Long Term Overall Survival: Anti-PD1
Nivolumab CA209-003
1
5-year OS
Pembrolizumab KEYNOTE-001
2
3-year OS
3 mg/kg Q2W (n=17)
Median OS: 20.3 months
Median OS: 24.4 months
1. Hodi FS, et al. AACR 2016 2. Robert, et al. ASCO 2016
ECOG PS ≤2
1−5 lines prior therapy (no prior ipi or anti-PD-1)
66% ≥2 prior therapies
ECOG PS 0/1
Untreated or pretreated (inc. prior ipi)
44% ≥2 prior therapies
